# A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

> **NCT05349643** · PHASE2 · COMPLETED · sponsor: **AmMax Bio, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Pigmented Villonodular Synovitis
- TGCT
- Tenosynovial Giant Cell Tumor

## Interventions

- **BIOLOGICAL:** AMB-05X

## Key facts

- **NCT ID:** NCT05349643
- **Lead sponsor:** AmMax Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-26
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349643, "A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05349643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*